# Ascletis to Present Study Results of Oral Small Molecule GIPR Agonist ASC48 and GLP-1R/GIPR/GCGR Triple Peptide Agonist ASC37 at ObesityWeek® 2026

- Source: PR Newswire M&A
- Published: 2026-11-02T08:50:00+00:00
- Category: Business
- Original: https://www.prnewswire.com/news-releases/ascletis-to-present-study-results-of-oral-small-molecule-gipr-agonist-asc48-and-glp-1rgiprgcgr-triple-peptide-agonist-asc37-at-obesityweek-2026-302925890.html
- Canonical: https://groundlevelnews.com/story/ascletis-to-present-study-results-of-oral-small-molecule-gipr-agonist--1d8ce8/

- Poster presentations feature preclinical in vitro and in vivo data of potentially first-in-class oral small molecule GIPR agonist ASC48 and next-generation once-monthly to once-quarterly GLP-1R/GIPR/GCGR triple peptide agonist ASC37 HONG KONG, Nov. 2, 2026 /PRNewswire/ -- Ascletis...

_Ground Level News shows a short summary only; the full article and all rights belong to PR Newswire M&A._